Nerandomilast is the first FDA-approved treatment for IPF in over a decade, targeting lung function decline. The FDA has ...

Aumolertinib had comparable efficacy to osimertinib when treating epidermal growth factor receptor ( EGFR )-mutant non-small ...

Building on AJMC ’s prior discussion with Patel on state-level Medicaid policy changes, this conversation explores how ...

David Rometo, MD, of UPMC, addresses stigma surrounding obesity and group setting weight loss intervention therapies and how ...

Panelists discuss how the greatest unmet needs include addressing poor outcomes in specific subsets like TP53-mutant disease, ...

AI-driven prior authorizations (PAs) are trusted by many clinicians, promising to streamline processes and reduce ...

Centrally acting agents like phentermine/topiramate and naltrexone/bupropion aid weight reduction but lack MASLD-specific data and carry potential risks such as hepatotoxicity, teratogenicity, or ...

Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.

Pharmacists face pressure to prioritize speed over patient education, impacting diabetes care quality and adherence to CGM devices. A CCS report found that pharmacists lack time for diabetes education ...

The ecosystem of care delivery outside the brick-and-mortar setting relies heavily on partnerships with community-based organizations and informal caregivers. These collaborations enhance care ...

Experts discuss the importance of a multidisciplinary approach in managing pediatric atopic dermatitis (AD), highlighting the need for collaborative care, accurate diagnosis, psychosocial support, and ...

Panelists discuss how negative symptoms create significant patient burden by appearing during the prodromal period in late adolescence and requiring a comprehensive biopsychosocial treatment approach ...